An Insight into Synthetic Strategies and Recent Developments of Dihydrofolate Reductase Inhibitors. Issue 43 (18th November 2021)

• Record Type: Journal Article
• Authors: Chawla, Pooja; Teli, Ghanshyam; Gill, Rupinder Kaur; Narang, Raj Kumar
• Is Part Of: ChemistrySelect. Volume 6:Issue 43(2021)
• Page Start: 12101
• Page End: 12145
• Publication Date: 2021-11-18
• Subjects: Antimicrobial -- antitumor agents -- dihydrofolate reductase -- folic acid -- molecular modelling -- synthetic methods -- structure-activity relationships; Chemistry -- Periodicals; 540.5
• DOI: 10.1002/slct.202102555
• Languages: English
• ISSNs: 2365-6549

Abstract

Abstract: The dihydrofolate reductase (DHFR) is a significant target in cancer, microbial infection, fungal infection, malaria, leishmaniasis, and tuberculosis, among other diseases. The DHFR gene was discovered in prokaryotes and eukaryotes in the late 1950s and is found in all dividing cells. DHFR inhibitors are used for a variety of medicinal purposes. Increased resistance to therapeutic agents such as anticancer, antibiotic, anti‐tuberculosis, and antifungal sparked interest in the development of potent, broad‐spectrum medicines to address the issues. DHFR is a critical target in the development of innovative solutions to address the issues. Methotrexate, trimethoprim, sulfonamides, pyrimethamine, aminopterin, methotrexate, edatrexate, and pralatrexate are only a few of the medications that target DHFR. These medications are known as DHFR inhibitors. These inhibitors block the enzyme dihydrofolate reductase, resulting in a folic acid synthesis pathway that is compromised. The DHFR is involved in the conversion of dihydrofolate to tetrahydrofolate. Purine, pyrazole, pyrimidine, triazole, oxadiazole, and other heterocyclic motifs have shown to have a potential effect on the DHFR. In the medicinal chemistry community, a better understanding of the so‐called enzyme and biochemical underpinnings responsible for enzyme selectivity has led to the development of improved, unique, and new treatments. Several researchers are working on DHFR inhibitors intensely, using a variety of synthetic techniques, molecular modelling, mechanistic studies, in‐vitro and in‐vivo biological evaluations, and structure‐activity relationships (SAR). This review, compiles the findings of several research groups during the last five years. The molecular biology of DHFR, its biosynthetic pathway, and the powerful structure of DFHR inhibitors discovered during the search are all included in this review. The study also includes the latest developments in synthetic methods, molecular docking, and structure‐activity relationships. Abstract : This review compiles the findings of several scientists during the last five years. The molecular biology of dihydrofolate reductase (DHFR), its biosynthetic pathway, and the powerful structure of DFHR inhibitors discovered during the search are all included here. The study also includes the latest developments in synthetic methods, molecular docking, and structure‐activity relationships.